In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma

References

• Hoeller C, Michielin O, Ascierto PA, Szabo Z, Blank CU. Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunol Immunother. 2016;65(9):1015–5. doi:10.1007/s00262-016-1860-3.
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Pilla L, Santinami M, Colombo M, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2006;18(2):226–232. doi:10.1093/annonc/mdl158.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma. JAMA. 2014;312(17):1744. doi:10.1001/jama.2014.13943.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Donahue H, Nishino M, Giobbie-Hurder A, Davis M, Bailey N, Ott PA, Hodi FS. Single institution experience of ipilimumab 3 mg/kg with sargramostim (GM-CSF) in metastatic melanoma. Cancer Immunol Res. 2015;3(9):986–991. doi:10.1158/2326-6066.CIR-15-0066.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Ruby CE, Hughes T, Slingluff CL. Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2(1):11. doi:10.1186/2051-1426-2-11.
   PubMedGoogle Scholar
• Franke V, Berger DMS, Klop WMC, Hiel B, Wiel BA, Meulen S, Wouters MWJM, Houdt WJ, Akkooi ACJ. High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a). Int J Cancer. 2019;145(4):974–978. doi:10.1002/ijc.32172.
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA. Cancer J Clin. 2017;67(6):472–492. doi:10.3322/caac.21409.
   PubMed Web of Science ®Google Scholar
• Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte K-W, Lehmann P, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–767. doi:10.1016/S1470-2045(16)00141-8.
   PubMed Web of Science ®Google Scholar
• Vuylsteke RJCLM, Molenkamp BG, Gietema HA, van Leeuwen PAM, Wijnands PGJTB, Vos W, van Diest PJ, Scheper RJ, Meijer S, de Gruijl TD. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res. 2004;64(22):8456–8460. doi:10.1158/0008-5472.CAN-03-3251.
   PubMed Web of Science ®Google Scholar
• Sluijter BJR, van den Hout MFCM, Koster BD, van Leeuwen PAM, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, et al. Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/CD141(+) dendritic cells and enhanced cross-presentation. Cancer Immunol Res. 2015;3(5):495–505. doi:10.1158/2326-6066.CIR-14-0165.
   PubMed Web of Science ®Google Scholar
• Molenkamp BG, van Leeuwen PAM, Meijer S, Sluijter BJR, Wijnands PGJTB, Baars A, van den Eertwegh AJM, Scheper RJ, de Gruijl TD. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res. 2007;13(10):2961–2969. doi:10.1158/1078-0432.CCR-07-0050.
   PubMed Web of Science ®Google Scholar
• Koster BD, Van Den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, Van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, Van Den Eertwegh AJM, et al. Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I–II melanoma: data from two randomized phase II trials. Clin Cancer Res. 2017;23(19):5679–5686. doi:10.1158/1078-0432.CCR-17-0944.
   PubMed Web of Science ®Google Scholar
• van de Ven R, van den Hout MFCM, Lindenberg JJ, Sluijter BJR, van Leeuwen PAM, Lougheed SM, Meijer S, van den Tol MP, Scheper RJ, de Gruijl TD. Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood. 2011;118(9):2502–2510. doi:10.1182/blood-2011-03-344838.
   PubMed Web of Science ®Google Scholar
• Molenkamp BG, Vuylsteke RJCLM, van Leeuwen PAM, Meijer S, Vos W, Wijnands PGJTB, Scheper RJ, de Gruijl TD. Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol. 2005;167(5):1301–1307. doi:10.1016/S0002-9440(10)61217-5.
   PubMed Web of Science ®Google Scholar
• de Gruijl TD, Sombroek CC, Lougheed SM, Oosterhoff D, Buter J, van den Eertwegh AJM, Scheper RJ, Pinedo HM. A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. J Immunol. 2006;176(12):7232–7242. doi:10.4049/jimmunol.176.12.7232.
   PubMed Web of Science ®Google Scholar
• Trigunaite A, Dimo J. Suppressive effects of androgens on the immune system. Cell Immunol. 2015;294(2):87–94. doi:10.1016/J.CELLIMM.2015.02.004.
   PubMed Web of Science ®Google Scholar
• Souyris M, Cenac C, Azar P, Daviaud D, Canivet A, Grunenwald S, Pienkowski C, Chaumeil J, Mejía JE, Guéry J-C. TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol. 2018;3(19):eaap8855. doi:10.1126/sciimmunol.aap8855.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, Li J, Mills GB, Shu Y, Li L, et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell. 2016;29(5):711–722. doi:10.1016/j.ccell.2016.04.001.
   PubMed Web of Science ®Google Scholar
• Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol. 2010;28(26):4038–4044. doi:10.1200/JCO.2009.27.4290.
   PubMed Web of Science ®Google Scholar
• Traub S, Demaria O, Chasson L, Serra F, Desnues B, Alexopoulou L. Sex bias in susceptibility to MCMV infection: implication of TLR9. Peterson KE, editor. PLoS One. 2012;7(9):e45171. doi:10.1371/journal.pone.0045171.
   PubMed Web of Science ®Google Scholar
• Surcel M, Constantin C, Caruntu C, Zurac S, Neagu M. Inflammatory cytokine pattern is sex-dependent in mouse cutaneous melanoma experimental model. J Immunol Res. 2017;2017:1–10. doi:10.1155/2017/9212134.
   Web of Science ®Google Scholar
• Leonard D, Eloranta M-L, Hagberg N, Berggren O, Tandre K, Alm G, Rönnblom L. Activated T cells enhance interferon-α production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. Ann Rheum Dis. 2016;75(9):1728–1734. doi:10.1136/annrheumdis-2015-208055.
   PubMed Web of Science ®Google Scholar
• Taleb K, Auffray C, Villefroy P, Pereira A, Hosmalin A, Gaudry M, Le Bon A. Chronic Type I IFN is sufficient to promote immunosuppression through accumulation of myeloid-derived suppressor cells. J Immunol. 2017;198(3):1156–1163. doi:10.4049/jimmunol.1502638.
   PubMed Web of Science ®Google Scholar
• Chen J, Deng C, Shi Q, Jiang J, Zhang Y, Shan W, Sun W. CpG oligodeoxynucleotide induces bone marrow precursor cells into myeloid-derived suppressor cells. Mol Med Rep. 2013;8(4):1149–1154. doi:10.3892/mmr.2013.1655.
   PubMed Web of Science ®Google Scholar
• Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res. 2011;17(7):1765–1775. doi:10.1158/1078-0432.CCR-10-2672.
   PubMed Web of Science ®Google Scholar
• Budhwani M, Mazzieri R, Dolcetti R. Plasticity of Type I interferon-mediated responses in cancer therapy: from anti-tumor immunity to resistance. Front Oncol. 2018;8:322. doi:10.3389/fonc.2018.00322.
   PubMed Web of Science ®Google Scholar
• Pelka K, Latz E. IRF5, IRF8, and IRF7 in human pDCs - the good, the bad, and the insignificant? Eur J Immunol. 2013;43(7):1693–1697. doi:10.1002/eji.201343739.
   PubMed Web of Science ®Google Scholar
• Sichien D, Scott CL, Martens L, Vanderkerken M, Van Gassen S, Plantinga M, Joeris T, De Prijck S, Vanhoutte L, Vanheerswynghels M, et al. IRF8 transcription factor controls survival and function of terminally differentiated conventional and plasmacytoid dendritic cells, respectively. Immunity. 2016;45(3):626–640. doi:10.1016/j.immuni.2016.08.013.
   PubMed Web of Science ®Google Scholar
• Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu K, et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest. 2013;123(10):4464–4478. doi:10.1172/JCI68189.
   PubMed Web of Science ®Google Scholar
• Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1540–1554.e12. doi:10.1016/j.cell.2016.11.022.
   PubMed Web of Science ®Google Scholar
• Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, Chapman R, Hertzog PJ. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013;41(Database issue):D1040–D1046. doi:10.1093/nar/gks1215.
   PubMedGoogle Scholar
• Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci. 1998;95(25). doi:10.1073/pnas.95.25.14863.
   Web of Science ®Google Scholar